There were 1,496 press releases posted in the last 24 hours and 442,035 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image